Nitroxide-loaded hexosomes provide MRI contrast in vivo.

Area of Science:

• Nanotechnology
• Biomedical Imaging
• Materials Science

Background:

• Magnetic resonance imaging (MRI) contrast agents are crucial for diagnostic imaging.
• Current gadolinium-based agents face toxicity concerns.
• Nitroxide-based agents offer an alternative but require effective delivery systems.

Purpose of the Study:

• To synthesize and screen nitroxide lipids within lipid nanoparticles for MRI contrast enhancement.
• To develop a lower-toxicity nanoparticle formulation with improved performance.
• To evaluate the in vivo efficacy and safety of the novel contrast agents.

Main Methods:

• Synthesis of a library of nitroxide lipids.
• Incorporation of lipids into cubic-phase lipid nanoparticles (cubosomes).
• Formulation of the most effective nitroxide lipid into lower-toxicity hexosomes.
• In vivo MRI contrast assessment in live rats.

Main Results:

• Screening identified effective nitroxide lipids for MRI contrast.
• Hexosome formulation demonstrated effective MR contrast in rat aorta and spleen.
• The new hexosomes exhibited significantly lower toxicity compared to previous cubosomes.
• Hexosomes achieved higher relaxivities comparable to clinical gadolinium agents.

Conclusions:

• Nitroxide lipids incorporated into hexosomes represent a new class of effective MRI contrast agents.
• Hexosomes offer a promising lower-toxicity and higher-relaxivity alternative to existing contrast agents.
• This formulation advances the development of safer and more efficient MRI contrast agents.